Form 4: ImmunityBio Director Acquires Stock Options

Cheryl Cohen, a director of ImmunityBio, Inc., acquired stock options for 77,633 shares of common stock on June 11, 2024.

Summary

• This Form 4 filing reports a transaction by Cheryl Cohen, a director of ImmunityBio, Inc.
• On June 11, 2024, Cohen acquired stock options for 77,633 shares of ImmunityBio's common stock at an exercise price of $5.96.
• The options vest on the earlier of June 11, 2025, or the day before the next annual meeting of stockholders, contingent upon continued service as a Service Provider.
• Following the transaction, Cohen directly owns options for 77,633 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director can be seen as a sign of confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon the reporting person's continued service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like ImmunityBio.
• Comparing the size and vesting schedule of this grant to those of similar companies (e.g., Amgen, Gilead, Biogen) would provide context on its relative value and incentive structure.
• The vesting conditions tied to continued service are also typical, aligning the director's interests with the long-term success of the company.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates